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Graphical Abstract 57 
Highlights  58 
 REVIVAL is a controlled, open-label multicentric study to compare the standard low 59 
doses of intravenous dexamethasone with low doses weight-adjusted of intranasal 60 
dexamethasone  61 
 Intranasal dexamethasone can reach more effectively than intravenous the respiratory 62 
tract  63 
 Intranasal dexamethasone can reach the central nervous system in therapeutic 64 
concentrations even at low doses  65 
 REVIVAL aims to add to the control of systemic inflammation, the control of 66 




COVID-19 has produced more than 176 million infected individuals and almost 3.2 million 69 
deaths worldwide. The infection results in a dysregulated systemic inflammation, multi-70 
organ dysfunction, and critical illness. Cells of the central nervous system (CNS) are also 71 
affected triggering a dysregulated neuroinflammatory response. 72 
Low doses of glucocorticoids (GCs) orally or intravenously administered has been proved to 73 
reduce mortality of moderate and severe COVID-19 patients. However, low doses 74 
administered by those routes do not reach therapeutic levels in the CNS. In contrast, if 75 
dexamethasone is administered by the intranasal route can result in therapeutic doses in the 76 
CNS even at low doses of the GC.  77 
Methods: This is an approved multicentric randomized controlled protocol to compare the 78 
effectiveness of low doses of intranasal dexamethasone versus intravenous administered in 79 
adult moderate and severe COVID-19 patients. The protocol is conducted in five health 80 
institutions in Mexico City. A total of 120 patients will be randomized in two groups 81 
(intravenous vs intranasal) at 1:1 ratio, both groups will be treated with these dexamethasone 82 
schemes for 10 days. The primary outcome of the study will be clinical improvement, defined 83 
as a statistically significant higher reduction in the NEWS-2 score in intranasally versus 84 
intravenously dexamethasone treated patients. The second outcome will be the reduction in 85 
mortality during hospitalization.   86 
Conclusions: This protocol is currently undertaken to improve the efficacy of the standard 87 
therapeutic dexamethasone regimen for moderate and severe COVID-19 patients. 88 
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Trial registration: ClinicalTrials.gov identifier: NCT04513184 Registered November 12, 89 
2020 and was approved by COFEPRIS with identifier DI/20/407/04/36. People are currently 90 
being recruited. 91 
Keywords: Dexamethasone, intranasal administration, inflammation, neuroinflammation, 92 
COVID-19 93 




So far, the outbreak of COVID-19 has caused more than 176 million infected individuals and 96 
almost 3.2 million deaths worldwide (https://coronavirus.jhu.edu/map.html) with a current 97 
global case-fatality ratio of 2.1%, the most affected geographic region are the Americas with 98 
a case-fatality ratio of 2.6%.  99 
Several factors predict a poor outcome for COVID-19 patients, such as comorbidities 100 
(diabetes, hypertension, obesity) and aging with an underlying dysregulated inflammatory 101 
response1. Other relevant factors include SARS-CoV-2 neurotropism/neuroinvasiness 2-9. In 102 
fact, the viral RNA was observed in the brain of patients that deceased by severe acute 103 
respiratory syndrome due to COVID-19 infection 10-12. Likewise, it was reported evidence 104 
of astrocytic activation and neuronal damage in severe COVID-19 patients, which present 105 
elevated plasmatic levels of GFAP and NfL 13. Other authors have evaluated astrocytes 14 106 
and neurons in 2D o 3D cultures showing an extensive infection 15,16. The infection of cells 107 
of the Central Nervous System results in the expression of PAMPs and DAMPs that trigger 108 
a neuroinflammatory response. The exacerbated systemic inflammation with the 109 
consequent breakdown of the blood-brain barrier and the migration of cells and peripheral 110 
inflammatory mediators also contribute to increase to the in situ generated 111 
neuroinflammatory response. Together, this dysregulated and sustained neuroinflammation 112 
can add to peripheral damage, central (CNS) damage, which may contribute to the multi-113 





Natural history of SARS-CoV-2 infection 117 
A clinical staging system has been proposed in SARS-CoV-2 infection as follow, early 118 
infection (Stage I, mild), pulmonary involvement (Stage IIa, moderate) without hypoxia, or 119 
with hypoxia (Stage IIb), and finally Stage III (systemic hyperinflammation) 17 (Figure 1).  120 
After exposure to SARS-CoV-2, virus gains host access through the nasal cavity and 121 
respiratory airway. During early infection (Stage I), mild and non – specific symptoms may 122 
be observed (fever, malaise, and asthenia), upon this prodromic phase virus binds its target 123 
ACE2, TMPRSS2 18, 19 and more recently NRP-1 20,21. These receptors are highly present on 124 
several tissues including the olfactory neuroepithelium (less in the sensitive olfactory 125 
neurons) and lung 19-22, consequently, the infection can be established in the lungs (Stage II) 126 
and lead to viral pneumonia, cough, and fever with or without hypoxia. Here the SARS-CoV-127 
2 PAMPs will be recognized by TLR3, TLR7 and TLR8 in the endosome but also in the RIG-128 
1 like receptor in the cytosol 23. The virus can also reach the CNS through the olfactory and 129 
trigeminal nerves terminal. Once in the CNS it can infect and damage endothelial, pericytes 130 
and neural cells that expressed ACE2, NRP-1 receptors 20, 21 promoting neuroinflammation 131 
(Figure 1). CNS viral involvement is related to headache, dizziness, and ataxia, but infection 132 
also may progress to the whole brain including the brainstem 5, 6. Finally, in a minority of 133 
infected-patients disease progresses to Stage III where a hyperinflammatory syndrome (the 134 
sustained production of proinflammatory cytokines including IL-1β and TNFα) is observed, 135 
with mitochondrial and lysosomal damage, expressing elevated proinflammatory cytokines, 136 
reactive oxygen species (ROS), and the hyperactivation of P2X7 receptors. These processes 137 
induce inflammasome activation (which increased IL-6 levels) and lead to pyroptosis which 138 
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determines a persistent inflammatory cycle by disseminating viral antigens and RNA in the 139 
circulation. Thereafter, it is possible the generation of immune complex and its deposition in 140 
target organs 23-25. During this phase, sustained neuroinflammation may exacerbate the 141 
neuronal injury, therefore spreading damage and contributing towards central respiratory 142 
failure besides other signs of systemic organ involvement resulting in multi-organ 143 
dysfunction 17.  144 
A crucial strategy to treat COVID-19 patients seems to be the control of neuroinflammation 145 
and systemic inflammation. For this purpose, it is important to consider how the virus invades 146 
the human organism. The most frequent form is the intranasal route which allows a direct 147 
access to both, the respiratory and the central nervous systems through neural pathways 5; 15-148 
18. Coronaviruses including SARS-CoV-2 can infect brainstem neurons associated with 149 
cardio-respiratory control, which induces central alterations of pulmonary function 5; 26-29. In 150 
fact, COVID-19 neurological clinical symptoms particularly nausea, vomiting, and dysgeusia 151 
appear to involve the dorsal vagal complex (DVC) and the nucleus tractus solitary (NTS) 152 
linked to the control of several autonomic functions 26. The NTS is a well-known target of 153 
neuro-immune activation 33, and its ascending projections reach the hypothalamus 154 
(hypothalamic paraventricular nucleus) involved in the HPA axis activation while other NTS 155 
projections come to the rostral ventrolateral medulla (RVM), which controls respiratory and 156 
cardiovascular functions 34.  157 
The viral infection in respiratory and central nervous system cells promotes the expression 158 
of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 159 
patterns (DAMPs) signals that in turn trigger inflammasome and oxidative stress 23,35. Later 160 
9 
 
during infection, inflammatory response may become dysregulated extending the initial 161 
damage caused by the infection.  162 
Adrenal affection in SARS-CoV-2 infection 163 
Critically ill-patients of different pathologies frequently show adrenal insufficiency which 164 
may increase morbidity and mortality 36, 37. COVID-19 might affect the hypothalamic-165 
pituitary-adrenal (HPA) axis as well. Hypothalamic and hypophysis tissues do express ACE2 166 
and can therefore be viral targets 38. The virus may directly damage the hypothalamus as well 167 
as the pituitary leading to hypothalamo-pituitary dysfunctions. In fact, since SARS outbreak 168 
in 2003, it was observed that coronavirus affects the HPA axis, and vasculitis was 169 
demonstrated by autopsy studies in several organs including adrenal glands, particularly 170 
adrenal cortical cells undergo degeneration and necrosis 39. Although the full spectrum of 171 
COVID-19 endocrinological manifestations within long-term is still unclear, several 172 
endocrine alterations have been reported in SARS survivors, as well as hypocortisolism, and 173 
hypothyroidism, and low levels of dehydroepiandrosterone, which suggested a transient 174 
hypothalamic-pituitary dysfunction 40. Recently, an Arabian study in 28-patients reported the 175 
adrenal response to an acute COVID-19 infection, the median morning cortisol level was 196 176 
(31-587) nmol/L, the ACTH median level of 18.5 (4-38ng/L). Interestingly, severe forms 177 
patients had lower cortisol and ACTH 41. In addition, in other autopsy studies, edema, 178 
neuronal degeneration and evidence of viral genome were found in the hypothalamus 42 Thus, 179 
in the presence of subacute thyroiditis or adrenal insufficiency, corticosteroid therapy should 180 
help in reduced high amounts of thyroid hormones, and replace adrenal function, improving 181 




Dexamethasone sodium phosphate (ALIN, injectable solution. Chinoin Laboratory) is a 184 
highly soluble glucocorticoid with a neutral pH 7-8.5, which did not injury the nasal mucosa. 185 
This synthetic steroid is an anti-inflammatory and immunomodulator drug that inhibits 186 
prostaglandins and leukotrienes synthesis, platelet activation, and coagulation through 187 
regulation of transcriptional factors such as NFK-β y AP-1 43,44. In addition, it can sensitize 188 
the cells to extracellular ATP during NLRP3 induction, which enhances the release of 189 
proinflammatory molecules 45. In addition, it has been reported that DXM exerts important 190 




       Figure 1. 193
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Dexamethasone a potent anti-inflammatory drug 194 
Considering that complications of COVID-19 result from exacerbated and uncontrolled 195 
peripheral inflammation and neuroinflammation, derived from the so-called cytokine storms, 196 
at least three important and key points have been considered in the use of DXM for the 197 
treatment of victims of the Coronavirus: the timing, the dose, and the route of administration 198 
of the steroid. First, the drug would not be applied from the beginning of the infection, the 199 
time at which the inflammation favors the host. It should be given to promote the installation 200 
of an adaptive immune response and thus control the infection. A low dose of DXM (6 mg 201 
per patient for 10 days) applied to quickly and effectively control pulmonary inflammation 202 
with minimal negative side effects 47. In addition, the intranasal route would allow direct 203 
access of the DXM to the CNS, thereby controlling the sustained neuroinflammation 204 
provoked by damage to infected astrocytes, neurons and microglia during the progression of 205 
COVID that cause the fatal central respiratory and cardiac failure in these patients. 206 
It is well known that drugs administered intranasal usually permit higher bioavailability in 207 
CNS without the need of BBB pass or hepatic degradation, in comparison with similar 208 
intravenous doses administered in experimental models 55, 56-58. In addition, the 209 
administration of DXM by this route induces an inflammatory control by arriving directly to 210 
the respiratory system, more effectively and quickly than by using intravenous route 56-59. 211 
DXM prevents the binding of ACE2 to spike protein of SARS-CoV-2 and can bind LYS353, 212 
an active residue of RBD 60, and reduces ACE2 expression in several types of cells by 213 
suppressing type I interferon expression 61, can also downregulate neutrophils extracellular 214 
traps, possibly through Toll-like receptor regulation 62. It is known that hyper inflammation 215 
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is related to high levels of NETs which is related to ARDS in which neutrophilia predicts 216 
thrombosis and poorer outcomes 63, 64. 217 
METHODS 218 
Trial design 219 
The “REVIVAL trial” an interventional study, phase 2, multicentric randomized controlled 220 
in adult patients with confirmed COVID-19 diagnosis was designed to evaluate the efficacy 221 
of low doses of intranasal DXM compared to intravenous administration in patients of five 222 
COVID-19 referral centers in Mexico City. This protocol is supported in part by the 223 
Institutional grant "Programa de Investigación para el Desarrollo y la Optimización de 224 
Vacunas, Inmunomoduladores y Métodos Diagnósticos del Instituto de Investigaciones 225 
Biomédicas", UNAM (DGAPA-UNAM, PAPIIT IN201020), as well as by another specific 226 
grant provided by the Mexican Ministry of Foreing Affairs (Secretaria de Relaciones 227 
Exteriores) and Mexican Agency for International Development Cooperation (AMEXCID) 228 
with identifier: 318.01 fund MEX-CHI. This trial is being coordinated at the Department of 229 
Immunology of the Biomedical Research Institute, UNAM. 230 
Settings 231 
This clinical trial is being conducted at the following Institutions “Hospital General de 232 
México Dr. Eduardo Liceaga”, “Instituto Nacional de Neurología y Neurocirugía Manuel 233 
Velasco Suárez”, “Instituto Nacional de Cardiología Ignacio Chavez”, “COVID-19 unit at 234 




Eligibility criteria  237 
Inclusion criteria includes patients of both sexes, (non-pregnant female) 18 years of age and 238 
under 90 years, with presumptive SARS-CoV-2 infection with more than 5 days of clinical 239 
evolution and with moderate to severe symptoms requiring oxygen support or high flux 240 
mechanical ventilation (NEWS-2 ≥ 5), abnormal CT- chest scan CO-RADS >3. Patients 241 
diagnosed with atypical pneumonia, confirmed by chest images and oxygen saturation 242 
(SpO2) less than 93% in ambient air or when a ratio of the partial pressure of oxygen (PaO2) 243 
and the fraction of inspired oxygen (FiO2) (PaO2: FiO2) was 300 mm Hg or less, and a 244 
confirmatory RT- PCR SARS-CoV-2 positive test. These patients will be allocated into the 245 
experimental group or the control group in a ratio 1:1 (two arms) (Fig. 2) according to the 246 
randomization. 247 
Exclusion criteria includes patients with RT-PCR SARS-CoV-2 negative test, those 248 
receiving previously GCs at high doses, by oral or intravenous administration, or severely 249 
immunosuppressed as in AIDS, pregnancy; autoimmune disease patients as well as those 250 
who have received outpatient treatment with steroids for more than 72 hours prior to hospital 251 
admission, older than 90 years, or with DXM allergy, risk for glaucoma or recurrent 252 
respiratory diseases.  253 
Elimination criteria will be considered in case of voluntary withdrawing or lacking informed 254 
consent, or imminent risk of death within 48 hrs. 255 
The pharmacovigilance staff of each hospital will perform a continuous monitoring each 72 256 





Groups and comparators 260 
The study will be carried out in two groups, group A (experimental) that will receive 261 
intranasal DXM, and group B (Control) that will receive intravenous DXM (Fig.2), based on 262 
the previously reported data, where the intranasal administration can reach the brain and 263 
bloodstream more quickly and efficiently 56-59. Group A will receive daily intranasally DXM 264 
at a dose of 0.12 mg / kg for the first three days, that will be followed by seven days at a dose 265 
of 0.06mg / kg. Group B will receive daily 6mg intravenous DXM. In both groups, a close 266 
follow-up will be done by the pharmacovigilance staff every 72 hours, they will assess 267 
whether it is appropriate for the patients to continue within the protocol. 268 
Procedures 269 
A double follow-up form (written and online) will be filled for each patient, and completed 270 
at the end of treatment or fatal outcome after randomization, whatever occurs first. Besides 271 
a daily clinical evaluation, blood and saliva samples will be collected every third day during 272 
the whole treatment period, to perform ancillary tests as SARS-CoV-2 viral load, functional 273 
immunological assessment (lymphocyte cytometry, cytokines / chemokines profile), as well 274 
as cortisol levels, among other analysis. All human samples will be stored at -70ºC until use. 275 
All patient’s personal data and medical information will be treated in a strictly confidential 276 





Participants  280 
The sample includes 120 adult patients between 18 and 90 year-olds, both sexes with 281 
moderate and severe forms of COVID-19. 282 
Sample size and Randomization 283 
The sample size was calculated with EPIDAT version 3.1.2 software, with the option 284 
“Sample size and surveillance curves” with an estimation of 50% increase in the proportion 285 
of patients free of mechanical ventilation [intranasal DXM 70% vs intravenous DXM 45%]. 286 
This value was estimated based on the data of the COVID-19 patients registered in Mexican 287 
hospitals with a confidence of 95%, power of 80% and proportion of losses of 10%, with 288 
these characteristics is obtained 60 per group. The randomization will be making with Sealed 289 
Envelope software. This software is a freeware [Online] available from: 290 
https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 5 May 2020]. This 291 
study is a multicenter randomized controlled trial. (Fig. 2)  292 
Confidentially 293 
Each patient who agrees to participate in the protocol will be assigned an identification 294 
number, which will be used to check out throughout the procedure. This code identifies the 295 
hospital of origin and the patient identification number. All the information collected during 296 
the procedure will be confidential and used for the research purpose only and follow up for 297 






The expected primary outcome is clinical improvement, defined as a two-point improvement 302 
of ordinal scale regarding the initial NEWS-2 score. The secondary expected outcome 303 
includes a reduction in mortality that will be follow-up during treatment (after 304 
randomization), as well as a reduction of the time required for mechanical ventilation and the 305 
length time of patient’s stay in hospital. Viral load, several other physiological parameters 306 
and the immune-inflammatory profile will also be evaluated before and after treatment (see 307 
above).  308 
Data collection and management 309 
The patient receives an informed consent letter, where the characteristics of the procedure 310 
are detailed, if he accepts, the letter will be signed and the patient will be randomized; saliva 311 
and nasopharyngeal sample will be taken to know the viral load and treatment will begin as 312 
indicated in figure 2; a clinical history will be made based on the initial results and physical 313 
inspection of the patient. 314 
The samples taken will be sent for specialized analysis following standardized operating 315 
procedures (SOP's) for the analysis. 316 
Plans to promote participant retention and complete follow-up 317 
All participants in the research protocol will receive specialized medical care, by monitoring 318 
continuously clinical, neurological, and neuropsychological studies. These evaluations will 319 
be carried out to monitor the evolution of the disease at 1, 3, 6, and 12 months after COVID-320 
19. Those participants presenting some functional decline post COVID will be received 321 
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medical treatment and neurorehabilitation. 322 
Likewise, for patients who present an adverse effect or health problem during its participation 323 
in the dexamethasone treatment study or derivate to it upon hospitalization, the General 324 
Hospital of Mexico Dr. Eduardo Liceaga will take care of the necessary treatment and/or care 325 
until their resolution. In addition, patients will be monitored every 3 months for 1 year after 326 
the study 327 
Management 328 
The information collected during the procedure will be documented physically and digitally 329 
in an exact and precise way. Each complete patient report will be used by researchers in 330 
conjunction with the molecular and immunological tests to analyze the outcomes. The 331 
information collected will be treated as confidential, and only the global results will be 332 
published without showing the names of the patients, in case the data is required, the 333 
information can be request to the researchers with valid reasons. 334 
Analysis of outcomes 335 
A database will be built, and a descriptive statistic will be performed. The data distribution 336 
will be analyzed and compared with DXM route of administration with a multivariable 337 
analysis: nested ANOVA with repeated measures and Markov test. The analysis will be done 338 









5. Conclusions 344 
Intranasal DXM at low doses could be a more effective therapeutic option to control 345 
inflammation and neuroinflammation during ARDS in severe and critical forms of SARS-346 
CoV-2 infection. In addition, it could aid the HPA axis upon this severe stress condition. 347 
DXM in low doses applied by systemic route although beneficial for COVID-19 patients, 348 
cannot reach effective therapeutic concentration in the CNS to control neuroinflammation. 349 
In contrast, intranasal administration of DXM is highly effective to control 350 
neuroinflammation as demonstrated in experimental models of several inflammatory 351 
conditions 44-47. Therefore, in the REVIVAL trial clinical protocol, we propose boosting the 352 
effect of DXM treatment at low doses in COVID-19 through an intranasal route of 353 
administration to reach CNS at therapeutic doses that may effectively reduce the morbidity 354 
and mortality in severe or critical COVID-19 patients, even more than that reported data in 355 
the RECOVERY trial. 356 
A randomized study in hospitalized COVID-19 patients (moderate and severe forms), the 357 
intranasal DXM at low doses (clinicaltrials.gov id: NCT04513184) is being tested. The 358 
clinical evolution and respiratory parameters of the patients receiving intranasal DXM 359 
(experimental treatment) is compared with recommended treatment of 6 mg of intravenously 360 
DXM (https://www.covid19treatmentguidelines.nih.gov/). Considering the prevalence of 361 
metabolic syndrome and obesity in Mexico, a therapeutic scheme weight-adjusted at low 362 
dose is being applied i.e., three-day schedule of 0.12 mg/kg and 7 days at 0.06 mg/kg. If the 363 
current approach results less prone to adverse effects but enough to reach CNS and control 364 
neuroinflammation as we hypothesized, there will be direct interest to extent this protocol to 365 
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several COVID hospitals of the National Healthy System in Mexico. In addition, it will be 366 
mandatory to increase the initial sample size (preliminary results) to publish it and share it 367 
with the International scientific community. 368 
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Figure Legends 432 
Figure 1. Inflammatory phenomenon associated with SARS-CoV-2 infection and its 433 
neurological and respiratory manifestations. The SARS-CoV-2 virus enters mainly by air and 434 
reaches the lungs through direct ventilation and the CNS through the olfactory and trigeminal 435 
nerve, the entry of the virus is facilitated by NRP-1, ACE2 receptors and the protein S 436 
activation by TMPRSS2. In the CNS, the virus infects neurons, glial cells, and endothelial 437 
cells, increasing the permeability of the BBB, and may cause cerebral edema and intracranial 438 
hypertension, as well as neuroinflammation. If the viral infection continues, the damage 439 
spreads throughout the body causing heart and systemic failure. This damage is associated 440 
with an increase in neuroinflammation, directed by microglia and oligodendrocytes, causing 441 
damage to the brain stem, and causing a dysfunctional state of the heart and lung. Likewise, 442 
in the lung, due to exacerbated inflammation and intravascular coagulation, respiratory arrest 443 
is induced that can lead to the patient death. The inflammation is conducted by the cellular 444 
activation trough TLR3, 7 and 8 for components from the virus (PAMPS) and subsequent 445 
production of pro-inflammatory cytokines (TNFα and IL 1β) and generation of ROS; those 446 
ROS can be able to modify the P2X7 receptor in the brain and activate the inflammasome by 447 
the decrease of K+. The activation of inflammasome increases the production of IL-6 and 448 
pyroptosis. 449 
Figure 2. Outline of the REVIVAL trial clinical protocol. Initially, patients will be informed 450 
about the clinical trial, if they accept and sign the consent, they will be randomized using the 451 
Sealed envelope® software. Group A receive DXM intranasally obtaining serum and a swab 452 
on days 0, 3, 6 and 10 post treatment. On the other hand, group B receive intravenous DXM, 453 
obtaining the same samples on the same days 0,3,6 and 10.  Throughout the study, the patients 454 
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are monitored. Once the results are obtained, these are analyzed to define if exist a 455 
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